Zukunftsfond Heilbronn

Zukunftsfond Heilbronn, established in 2005, is a private equity firm headquartered in Heilbronn, Germany. It specializes in investing in early-stage, innovative companies in the healthcare and technology sectors, supporting them from their initial startup phase through to maturity. The firm seeks promising ventures with strong market potential and experienced management teams, providing capital and resources to fuel their growth.

Thomas R. Villinger

Managing Director, CEO and Co-Founder

17 past transactions

Eleva

Venture Round in 2021
Eleva develops biological therapies in collaboration with pharmaceutical partners. Utilizing its unique moss-based production platform, Eleva creates superior biologics such as antibodies, replacement enzymes, and fusion toxins. The company has successfully advanced drug candidates into clinical phases.

MetisMotion

Seed Round in 2018
MetisMotion GmbH, founded in 2018 and headquartered in Munich, Germany, specializes in the development of advanced actuators designed for various industrial applications, including robotics, aviation, and automotive sectors. The company focuses on creating lightweight, high force-density actuators that enhance performance through significant reductions in weight and space. MetisMotion's technology integrates the advantages of solid-state actuators with traditional drive systems, facilitating the electrification of hydraulic systems to achieve greater force output and extended displacement capabilities. This innovative approach positions MetisMotion as a key player in driving efficiency and modernization within the actuator market.

ResuSciTec

Series B in 2016
ResuSciTec GmbH, established in 2010 in Freiburg im Breisgau, Germany, specializes in developing innovative therapies for patients experiencing acute circulatory failure. The company focuses on researching controlled whole-body reperfusion methods to improve patient outcomes during cardiac arrest. Led by Prof. Dr. med. Dr. hc Friedhelm Beyersdorf, ResuSciTec aims to advance resuscitation techniques and enhance cardiovascular care.

XENiOS

Seed Round in 2015
XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company offers a comprehensive range of products, including the iLA active platform for extrapulmonary lung support, iLA Membrane Ventilator for pumpless lung support, and various cannulas and pumps designed for cardiac surgery applications. Additionally, XENiOS provides innovative solutions such as the NovaTherm Heater/Cooler for blood temperature management and the deltastream series for monitoring and managing patient parameters during treatment. The company is uniquely positioned in the market by offering minimally invasive, disposable therapies that address both lung and heart conditions on a single platform, which is not available from other manufacturers. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG also delivers clinical application support, training, and customer service to healthcare providers. As of late 2016, it operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.

ProtaGene

Acquisition in 2013
ProtaGene is an analytical service provider specializing in the biopharmaceutical sector, particularly in the development of biologic therapeutics and cell and gene therapies. The company offers a comprehensive suite of protein and gene analytic capabilities, catering to the needs of biosimilar developers by facilitating the demonstration of biosimilarity. ProtaGene's services include peptide mapping, protein quantification, protein modification analysis, bioassays, impurity assessment, and detailed characterization of antibodies and related products. These offerings are designed to support clients throughout the product lifecycle, enabling advanced analytics that enhance biopharmaceutical development processes.

Compositence

Private Equity Round in 2013
Compositence is a manufacturer specializing in carbon and fiber composites for various industries, including automotive, wind energy, aerospace, machinery, and sports and leisure. The company focuses on providing machinery for the large-scale production of carbon fiber and glass fiber components, alongside software solutions for part design and simulation. By integrating advanced technologies, Compositence aims to enhance efficiency and innovation in composite manufacturing, catering to a diverse range of industrial applications.

Echobot Media Technologies

Series A in 2013
Echobot Media Technologies GmbH, founded in 2011 and based in Karlsruhe, Germany, specializes in online and social media monitoring through its SaaS application. The company serves over 300 clients across various industries, focusing on analyzing vast amounts of web data to provide actionable insights that enhance public relations and marketing strategies. Echobot's platform evaluates external information and current events in real-time, enabling businesses to refine their target audiences and improve their sales and marketing efforts. The company has established contracts with notable media organizations, including Axel Springer and Agence France Presse (AFP). Recognized for its innovation, Echobot won the German CyberChampion Awards in 2012 and is now poised for growth following a recent Series A investment aimed at expanding its presence in German-speaking markets and developing new products.

ResuSciTec

Series A in 2012
ResuSciTec GmbH, established in 2010 in Freiburg im Breisgau, Germany, specializes in developing innovative therapies for patients experiencing acute circulatory failure. The company focuses on researching controlled whole-body reperfusion methods to improve patient outcomes during cardiac arrest. Led by Prof. Dr. med. Dr. hc Friedhelm Beyersdorf, ResuSciTec aims to advance resuscitation techniques and enhance cardiovascular care.

Medos Medizintechnik

Acquisition in 2011
Medos Medizintechnik develops and manufactures medical devices for cardiac surgery, extracorporeal membrane oxygenation, and ventricle assist devices. Its products include VAD-Atrium-Cannulae; VAD-Apex-Cannulae; Arterial-VAD-Cannulae; X-Flow; DELTASTREAM; HILITE; HILITE Reservoirs; tubing Sets, which include machine-sets, table-sets, cardioplegia-sets, infusion-/transfusion-/re-transfusion and perfusion-sets, haemofilter-sets, pressure-measuring-sets, and pre-bypass-sets; surgical Sets; VAD System; heparin coating; arterial filter; and haemofilter. The company offers tubing sets and surgical sets, as well as provides assembly of indication specific surgical sets.

enymotion

Venture Round in 2008
Enymotion specializes in the development and production of ultra-quiet, zero-emission energy sources tailored for mobile applications. The company focuses on creating innovative mobile fuel cell systems that provide a self-sufficient power supply for recreational use, such as in caravans, boats, and utility vehicles. These systems utilize the caloric equivalent of conventional fuels or liquid gas, delivering power without noise or exhaust emissions. By enabling consumers to consume power independently, Enymotion positions itself as a leader in sustainable energy solutions for outdoor and recreational lifestyles.

dataglobal

Venture Round in 2008
dataglobal is a software company offering enterprise information management and data management solutions to optimize digital business processes. Its data center storage management software provides an integrated suite to analyze, monitor, quantify, qualify, offload, control, archive, and delete data across IT storage environments, including ERS migration, ERS archive, ERS chargeback, and ERS storage performance. The firm also supplies digital workplace software for ECM, DMS, and email security, supporting governance, risk management, compliance, and eDiscovery. dataglobal helps organizations optimize systems such as file servers, mail servers, SharePoint, ERP, and other applications, while enabling information from heterogeneous sources to be leveraged for added value. With more than 500 installations in over 40 countries and a global partner network, its clients include Audi, Deutsche Bank, T-Systems, NDR, the Bundesnetzagentur, and Rhenus Logistics. Headquartered in Heilbronn, Germany, the company also maintains an office in Los Gatos, California.

IoLiTec Ionic Liquids Technologies

Venture Round in 2008
IoLiTec Ionic Liquids Technologies GmbH specializes in the development, production, and sale of ionic liquids for a wide range of applications, including synthesis, catalysis, analytics, electroplating, biotechnology, and sensor technology. The company offers additional products such as nanotech coatings, energy and cleantech innovations, and fine chemicals. Founded in 2003 and based in Heilbronn, Germany, IoLiTec provides consulting services and feasibility studies, aiding in the development of new products and applications derived from ionic liquids. The company collaborates with partners across various industries, including chemical, engineering, electrical, and automotive sectors, serving both small and medium-sized enterprises as well as larger global corporations.

Schwarzer Cardiotek

Venture Round in 2008
Schwarzer Cardiotek GmbH, based in Heilbronn, Germany, specializes in the development, manufacture, and distribution of measurement systems for functional diagnostics in left/right-heart catheterization. The company's focus is on hemodynamic and electrophysiological measuring stations, as well as data management solutions tailored for interventional cardiology. Their product range includes combined hemo-electrophysiology, electrophysiology, hemodynamics, and data management solutions. These systems are fully integrated with documentation and reporting features and compatible with major X-ray manufacturers. With over 1,000 systems installed globally and a market presence spanning more than 60 years, Schwarzer Cardiotek is recognized for its expertise in cardiology diagnostics. The company was founded in 1938 and rebranded from Schwarzer GmbH to Schwarzer Cardiotek GmbH in June 2014.

seleon GmbH

Acquisition in 2007
Seleon GmbH is a Heilbronn, Germany-based company that specializes in the development and manufacturing of electronic and mechanical equipment for the healthcare industry. Established in 1998, the company has grown into a prominent provider of medical technology services. Its product portfolio includes Trans-Nasal Insufflation (TNI), designed for patients with mild sleep apnea and hypopnea, as well as Cpeak Tremor Analysis Software for analyzing human tremors. Additionally, Seleon offers radiation equipment and systems for image recording and analysis. The company collaborates closely with clients worldwide to create tailored solutions, leveraging the expertise of its team, which includes physicists, engineers, and consultants. Seleon also provides a range of consulting services, such as lifecycle management and regulatory guidance, aimed at enhancing project planning and execution for medical technology firms.

smartgas mikrosensorik

Seed Round in 2007
smartGAS Mikrosensorik GmbH specializes in the development, manufacturing, and sale of infrared gas sensors, particularly non-dispersive infrared (NDIR) sensors. Founded in 2005 and headquartered in Heilbronn, Germany, the company provides solutions for original equipment manufacturers and offers customized products tailored to specific applications. Its sensors are utilized across various sectors, including analysis, refrigeration, air conditioning, high voltage engineering, safety engineering, intelligent ventilation, and food storage. smartGAS Mikrosensorik distributes its products through a network of partners in Europe, Asia, Russia, the United States, and Canada, ensuring a broad reach for its reliable and cost-effective gas detection technologies.

greenovation Biotech

Series B in 2006
Greenovation Biotech GmbH is a biopharmaceutical company based in Heilbronn, Germany, specializing in the production of glycoproteins aimed at treating orphan diseases. The company’s product portfolio includes Moss-aGal, a therapeutic candidate for Fabry disease; Moss-FH, a recombinant protein for atypical hemolytic uremic syndrome (aHUS); and Moss-GBA, intended for enzyme replacement therapy in Gaucher's disease patients. Greenovation Biotech has developed an innovative moss bioreactor technology that serves as a safe and cost-effective production platform for biopharmaceuticals, enhancing the activity of therapeutic proteins, including antibodies. In addition to its proprietary products, the company provides contract development and manufacturing services, utilizing its BryoMaster expression strains, which are intact moss plants regenerated from transgenic cells, and its photoautotrophic fermentation process that is free from antibiotics and animal-derived components. Founded in 1999, Greenovation Biotech is committed to advancing biopharmaceutical production through sustainable and innovative approaches.

RevoAI GmbH

We enable engineers to deliver incredible products. Faster.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.